Background: Doripenem, an investigational parenteral carbapenem, exhibits a broad
spectrum of activity and favorable potency. As resistance emergence increases in the Asia …

To investigate the antibacterial resistance to doripenem in China and to understand the
distribution trends of resistant bacteria. All the clinical isolates were collected from hospitals …

In the study we tested drug sensitivity to 3 carbapenems (doripenem, imipenem and
meropenem) of Gram-negative clinical isolates from Southern Poland. Material and …

Sir, In a previous study we demonstrated that doripenem, the most recently approved
carbapenem, exhibited antimicrobial activity similar to that of imipenem or meropenem in an …

Methods: A total of 117 strains of multidrug-resistant (MDR) non-fermenting Gram negative
bacteria isolated from non-duplicate samples were collected consecutively. We included …

Doripenem is a broad-spectrum parenteral carbapenem with enhanced activity against
Pseudomonas aeruginosa. While the initial dosing recommendation for renally competent …

Carbapenem-and fluoroquinolone-non-susceptible Acinetobacter baumannii were obtained
from four nosocomial pneumonia patients who were clinically cured following combination …

The aim of this study was to determine the current susceptibility of hospital isolates of
contemporary Gram-negative pathogens to the carbapenems doripenem, imipenem and …

Objective: Doripenem is a new carbapenem that has broad-spectrum activity against
bacterial pathogens commonly responsible for nosocomial pneumonia (NP). It has several …

BACKGROUND Doripenem is the most recently introduced carbapenem, with a broad
spectrum of antimicrobial activity. Preliminary data indicated that activity is optimized by …